Lamivudine Sandoz

Lamivudine Sandoz

lamivudine

Manufacturer:

Sandoz

Distributor:

Zuellig
Concise Prescribing Info
Contents
Lamivudine
Indications/Uses
Treatment of HBV infection associated w/ evidence of HBV replication & active liver inflammation.
Dosage/Direction for Use
Adult 100 mg once daily. Ped patient (2-17 yr) 3 mg/kg once daily up to a max daily dosage of 100 mg.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity reaction (eg, anaphylaxis).
Special Precautions
Risk of lactic acidosis & severe hepatomegaly w/ steatosis, including fatal cases w/ women, obesity & prolonged nucleoside exposure; patient w/ known risk factors for liver disease. Monitor hepatic function w/ clinical & laboratory follow-up for at least several mth in patients who discontinue antihepatitis B therapy. Not for patients co-infected w/ HBV & HIV. HIV-1 resistance may emerge in chronic hepatitis B-infected patients w/ unrecognized or untreated HIV-1 infection. Do not coadminister w/ other lamivudine- or emtricitabine-containing products. Patients w/ YMDD-mutant HBV; renal impairment. Pregnancy & lactation. Ped patients <2 yr. Elderly.
Adverse Reactions
Thrombocytopenia, stomatitis, hyperglycemia, weakness, anemia (including pure red cell aplasia & severe anemias progressing on therapy), lymphadenopathy, splenomegaly; lactic acidosis & steatosis, post-treatment exacerbation of hepatitis, pancreatitis; anaphylaxis, urticaria, cramps, rhabdomyolysis; paresthesia, peripheral neuropathy; abnormal breath sounds/wheezing; alopecia, pruritus, rash.
MIMS Class
ATC Classification
J05AF05 - lamivudine ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Presentation/Packing
Form
Lamivudine Sandoz FC tab 100 mg
Packing/Price
28's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in